Veracyte said Q1 revenue grew 21% and earnings per share quadrupled from a year earlier, with margins expanding sharply. The company’s main prostate and thyroid cancer tests continued to post double-digit sales growth, signaling strong underlying demand and improving profitability.
Veracyte said Q1 revenue grew 21% and earnings per share quadrupled from a year earlier, with margins expanding sharply. The company’s main prostate and thyroid cancer tests continued to post double-digit sales growth, signaling strong underlying demand and improving profitability.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.74
Ticker Sentiment
